Emitents | Olainfarm, AS (213800WCG52W62ENOP27) |
Veids | Finanšu pārskati |
Valoda | EN |
Statuss | Publicēts |
Versija | |
Datums | 2013-05-30 21:25:53 |
Versijas komentārs | |
Teksts |
Olaine, 30.05.2013
“OlainFarm” sales in Q1 2013 reach 12.6 million
lats
AS “OlainFarm” sales during the 1st quarter of 2013 have reached
12.6 million lats (17.9 million euro), which represents a 4%
year-on-year growth. Thus, based on sales figures, Q1 2013 has been
the most successful first quarter of the year in the company’s
history. The biggest increases in sales during Q1 2013 were
achieved in Kyrgyzstan (+78%), Belarus (+72%), Uzbekistan (+64%)
and Great Britain (+51%).
“This year, we are planning to expand our operations by acquiring
new pharmacies and other pharmaceuticals-related companies. The
first step is our purchase of shares in SIA “Silvanols”, which will
allow AS “OlainFarm” to involve itself more actively in medical
equipment and food supplement sub-segments. AS “OlainFarm” recently
received a corporate income tax exemption for approved investments
in our project “Introduction of new products and improved exporting
capacity”, which is a significant government-level acclaim of our
work. We will continue to strengthen our positions and to develop
by ensuring that announcements of AS “OlainFarm” record-breaking
quarterly results become a regular occurrence,”
says Valērijs Maligins, Chairman of the Board of AS
“OlainFarm”.
During the 1st
quarter of 2013 AS “OlainFarm” sales continued to increase in all
of the company’s main markets, except for Ukraine, where they
decreased by 71% year-on-year. However, SIA “OlainFarm” had already
expected import difficulties in the Ukraine market and made extra
shipments to the country in the 4th quarter of 2012. Major sales
markets of AS “OlainFarm” during Q1 2013 were Russia, Ukraine,
Latvia, Belarus and the UK.
AS
“OlainFarm” consolidated profit and loss statement for the 1st
quarter of 2013 shows that the company has made a net profit of
1.95 million lats (2.78 million euro), which is a 19% year-on-year
decrease. Reduction of sales to Ukraine has made a significant
impact on the company’s profitability.
During the 1st
quarter of 2013 4 products have been registered in Ukraine,
Turkmenistan, Russia and Belarus. These include Kapikor (Olvazol),
a heart drug which can be used for strengthening the heart and
cardiovascular system in acute cases of myocardial infarction or
stroke. The company has also reached an agreement about the
commencement of product registration process in Turkey, while work
has been started on developing several new final dosage
forms.
AS “OlainFarm”
budget and operating plan for 2013 sets targets for consolidated
sales to reach 59 million lats (84 million euro) and net profit to
reach 11.5 million lats (16.4 million euro). According to the
unaudited report, during the 1st quarter of 2013 21% of the annual
sales target and 17% of the annual profit target have been
met.
A/s OlainFarm is one of the
biggest pharmaceutical companies in Latvia with 40 years of
experience in production of medication and chemical and
pharmaceutical products. A basic principle of company's operations
is to produce reliable and effective top quality products for
Latvia and the rest of the world. Products made by the Group are
being exported to more than 30 countries of the world, including
the Baltics, Russia, other CIS, Europe, Asia, North America and
Australia.
Information
prepared by:
Salvis
Lapins
Member of the
Board
A/s
„OlainFarm”
Tel: +371 6 7013
717
e-mail:
Salvis.Lapins@OlainFarm.lv
|
Pielikumi |